search
Back to results

Effectiveness of Trauma Therapy in Patients With PTSD and Comorbid Psychotic Disorder (PEPSY)

Primary Purpose

Post Traumatic Stress Disorder, Psychotic Disorders, Psychosis

Status
Recruiting
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Prolonged Exposure
Sponsored by
University of Hamburg-Eppendorf
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Post Traumatic Stress Disorder focused on measuring PEPSY, Prolonged Exposure, trauma psychotherapy

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • have a diagnosis of a Post Traumatic Stress Disorder (PTSD spectrum disorder (ICD-10, F43.1, confirmed by SCID-5 and CAPS)
  • have a diagnosis of a schizophrenia spectrum disorder (ICD-10, F2, confirmed by SCID-5)
  • patients will be reporting distressing AH for at least six months (to be beyond the startle and adjustment phase ) and score ≥ 3 on either item 8 or item 9 of the PSYRATS-AH;
  • be ≥ 18 years of age
  • good knowledge of the German language
  • Willingness to participate in randomization and trauma-focused therapy

Exclusion Criteria:

  • Changes in neuroleptic or antidepressant therapy within the last 4 weeks (exclusion of drug effects)
  • Any substance addiction with continued use other than nicotine and / or caffeine addiction
  • IQ of 70 or less
  • Acute suicidality
  • Pregnant women

Sites / Locations

  • University HamburgRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Experimental: Prolonged Exposure + Treatment as usual

Waiting-Controll-Group

Arm Description

Participants in this arm will receive 16 weekly sessions with Prolonged Exposure Therapy (RT) over 4 months in addition to their treatment as usual. Interventions: Behavioral: Prolonged Exposure Therapy Other: Treatment as usual

Treatment as usual Treatment as usual will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally. Intervention: Other: Treatment as usual

Outcomes

Primary Outcome Measures

Clinician-Administered PTSD Scale for DSM-5 (CAPS)
The severity of the PTSD symptoms associated distress. The distress factor score of the CAPS is the primary outcome as this is what has been prioritized by patients and is relevant to functioning. Confirmatory analysis will be conducted based on the intent-to-treat population (ITT), defined on the basis of the ITT principle. The aim is to show that the intervention group is superior to the control meaning that the mean score at 6 months adjusted for the baseline value is lower in the intervention group than in the control group. Lower scores indicate less distress.
Subjective PTSD symptoms
Posttraumtatic Stress Symptom Scale Self-Report (PSSI, Foa et al., 1993)

Secondary Outcome Measures

The Psychotic Symptom Rating Scales-AH-Distress factor score (PSYRATS-AH)
Auditory hallucination associated distress. The distress factor score of the PSYRATS-AH is the secondary outcome. The aim is to show that the intervention group is superior to the control meaning that the mean score at 6 months adjusted for the baseline value is lower in the intervention group than in the control group. Lower scores indicate less distress.
Welleing
Wellbeing: Short Warwick-Edinburgh Mental Wellbeing Scale (SWEMWBS, NHS Health Scotland, University of Warwick and University of Edinburgh, 2007)

Full Information

First Posted
May 27, 2021
Last Updated
May 27, 2021
Sponsor
University of Hamburg-Eppendorf
search

1. Study Identification

Unique Protocol Identification Number
NCT04911010
Brief Title
Effectiveness of Trauma Therapy in Patients With PTSD and Comorbid Psychotic Disorder
Acronym
PEPSY
Official Title
Effectiveness of Trauma Therapy Using Prolonged Exposure for the Treatment of Post-traumatic Stress Disorder (PTSD) in Patients With Comorbid Psychotic Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Recruiting
Study Start Date
January 20, 2021 (Actual)
Primary Completion Date
January 2024 (Anticipated)
Study Completion Date
September 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Hamburg-Eppendorf

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Effectiveness of trauma therapy using prolonged exposure for the treatment of post-traumatic stress disorder (PTSD) in patients with comorbid psychotic disorder
Detailed Description
Background and goals: Patients with psychotic disorders often report traumatizing experiences in their biography and show symptoms of a trauma-related disorder. It is assumed that around 30 percent of patients with a psychotic disorder also meet the criteria for PTSD. For the vast majority of patients, psychosis is the focus of mostly pharmacological treatment, while PTSD is not part of the therapy. In a first randomized controlled study, van den Berg's Dutch working group was able to show that psychosis patients with comorbid PTSD who were given a classic trauma exposure procedure showed a high response to PTSD symptoms (van den Berg et al., 2015). It is also important that in this study the trauma exposure did not lead to an increase in psychotic symptoms or undesirable side effects (e.g. suicidality). In order to examine the question of the generalizability of the effects, a randomized controlled study in the German-speaking health care system is necessary. In the following efficacy study in which psychosis patients with PTSD are treated using prolonged exposure. METHODS AND RESULTS: It is a multicenter, controlled, prospective, randomized study (RCT). It is investigated whether trauma therapy reduces PTSD and psychosis symptoms compared to the Treatment-As-Usual Waiting Group (TAU). The primary endpoint is the severity of the PTSD symptoms between the baseline measurement and the 6-month follow-up. Secondary endpoints are subjective PTSD symptoms, paranoia, hallucinations, and wellbeing.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post Traumatic Stress Disorder, Psychotic Disorders, Psychosis, Schizophrenia, PTSD
Keywords
PEPSY, Prolonged Exposure, trauma psychotherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
prospective, randomized, controlled, parallel-group, two-armed, multicentre, open trial
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental: Prolonged Exposure + Treatment as usual
Arm Type
Experimental
Arm Description
Participants in this arm will receive 16 weekly sessions with Prolonged Exposure Therapy (RT) over 4 months in addition to their treatment as usual. Interventions: Behavioral: Prolonged Exposure Therapy Other: Treatment as usual
Arm Title
Waiting-Controll-Group
Arm Type
No Intervention
Arm Description
Treatment as usual Treatment as usual will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally. Intervention: Other: Treatment as usual
Intervention Type
Behavioral
Intervention Name(s)
Prolonged Exposure
Other Intervention Name(s)
Trauma Therapy
Intervention Description
In the intervention condition, patients are treated with prolonged exposure in 16 hours of individual therapy immediately after the baseline measurement. The 16 individual therapeutic sessions take place 1 to 2 sessions per week over a period of 7 to 16 weeks. The individual therapeutic sessions are recorded on video with camera focus on the therapist. Parts of the prolonged exposure procedure (reliving the traumatic memory) are recorded on tape (via the patient's personal smartphone) so that the patient can listen to the recording as homework at home. The patients then take part in a post-treatment study diagnosis (T1).
Primary Outcome Measure Information:
Title
Clinician-Administered PTSD Scale for DSM-5 (CAPS)
Description
The severity of the PTSD symptoms associated distress. The distress factor score of the CAPS is the primary outcome as this is what has been prioritized by patients and is relevant to functioning. Confirmatory analysis will be conducted based on the intent-to-treat population (ITT), defined on the basis of the ITT principle. The aim is to show that the intervention group is superior to the control meaning that the mean score at 6 months adjusted for the baseline value is lower in the intervention group than in the control group. Lower scores indicate less distress.
Time Frame
6 months after baseline assessment
Title
Subjective PTSD symptoms
Description
Posttraumtatic Stress Symptom Scale Self-Report (PSSI, Foa et al., 1993)
Time Frame
6 months after baseline assessment
Secondary Outcome Measure Information:
Title
The Psychotic Symptom Rating Scales-AH-Distress factor score (PSYRATS-AH)
Description
Auditory hallucination associated distress. The distress factor score of the PSYRATS-AH is the secondary outcome. The aim is to show that the intervention group is superior to the control meaning that the mean score at 6 months adjusted for the baseline value is lower in the intervention group than in the control group. Lower scores indicate less distress.
Time Frame
6 months after baseline assessment
Title
Welleing
Description
Wellbeing: Short Warwick-Edinburgh Mental Wellbeing Scale (SWEMWBS, NHS Health Scotland, University of Warwick and University of Edinburgh, 2007)
Time Frame
6 months after baseline assessment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: have a diagnosis of a Post Traumatic Stress Disorder (PTSD spectrum disorder (ICD-10, F43.1, confirmed by SCID-5 and CAPS) have a diagnosis of a schizophrenia spectrum disorder (ICD-10, F2, confirmed by SCID-5) patients will be reporting distressing AH for at least six months (to be beyond the startle and adjustment phase ) and score ≥ 3 on either item 8 or item 9 of the PSYRATS-AH; be ≥ 18 years of age good knowledge of the German language Willingness to participate in randomization and trauma-focused therapy Exclusion Criteria: Changes in neuroleptic or antidepressant therapy within the last 4 weeks (exclusion of drug effects) Any substance addiction with continued use other than nicotine and / or caffeine addiction IQ of 70 or less Acute suicidality Pregnant women
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Susanne Sarkar, Dr.
Phone
00494042838-9699
Email
susanne.sarkar@uni-hamburg.de
First Name & Middle Initial & Last Name or Official Title & Degree
Tania Lincoln, Prof. Dr.
Phone
+49 40 42838-5360
Email
tania.lincoln@uni-hamburg.de
Facility Information:
Facility Name
University Hamburg
City
Hamburg
ZIP/Postal Code
20146
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Susanne Sarkar, Dr.
Phone
+49 40 42838-5374
Email
susanne.sarkar@uni-hamburg.de
First Name & Middle Initial & Last Name & Degree
Esther Wolfrom
Phone
+49 40 42838-5360
Email
klinische.psych@uni-hamburg.de

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Effectiveness of Trauma Therapy in Patients With PTSD and Comorbid Psychotic Disorder

We'll reach out to this number within 24 hrs